Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration ...
As cases of Alzheimer's disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of ...
A new report published by the Tufts Center for the Study of Drug Development (CSDD) validates longstanding data indicating that drugs intended to treat disorders of Central Nervous System (CNS) take ...
FREMONT, CA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ...
CNS-3D Inflammatory Organoids, designed to evaluate efficacy of anti-inflammatory drugs by quantifying their ability to ...
Electroencephalography (EEG) records neuronal activity inside the brain via electrodes placed on the scalp. As a real-time and dynamic method of recording ,EEG offers a direct window on neocortical ...
Polyrizon Ltd., a biotechnology company focused on intranasal drug delivery systems, has reported promising preclinical results for its hydrogel-based Trap & Target (T&T) platform, developed in ...
Beyond chronic diseases, CNS drug delivery is also a critical factor in biodefense and national security. As traditional drug-delivery approaches continue to face limitations, alternative methods ...
The Union Health Ministry has tightened the norms involving the supply and sale of central nervous system drug pregabalin, by ...
- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results